{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:24:00Z","timestamp":1786119840528,"version":"build-2736575974"},"reference-count":83,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1097\/bot.0b013e3181f9b389","type":"journal-article","created":{"date-parts":[[2011,6,8]],"date-time":"2011-06-08T05:45:23Z","timestamp":1307511923000},"page":"566-573","source":"Crossref","is-referenced-by-count":34,"title":["A Comprehensive Approach to Fragility Fractures"],"prefix":"10.1097","volume":"25","author":[{"given":"Brian J","family":"Rebolledo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aasis","family":"Unnanuntana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210212","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1359\/jbmr.2000.15.4.721","article-title":"Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis.","volume":"15","author":"Klotzbuecher","year":"2000","journal-title":"J Bone Miner Res"},{"key":"R3-10-20210212","first-page":"111","article-title":"Predictors of mortality after hip fracture: a 10-year prospective study.","volume":"66","author":"Paksima","year":"2008","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"R4-10-20210212","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00198-004-1740-0","article-title":"Factors associated with mortality and functional disability after hip fracture: an inception cohort study.","volume":"16","author":"Alegre-Lopez","year":"2005","journal-title":"Osteoporos Int"},{"key":"R5-10-20210212","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1532-5415.2000.tb02641.x","article-title":"Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture Intervention Trial Research Group.","volume":"48","author":"Ensrud","year":"2000","journal-title":"J Am Geriatr Soc"},{"issue":"Suppl 6","key":"R6-10-20210212","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2106\/JBJS.I.00521","article-title":"Osteoporosis disease management: what every orthopaedic surgeon should know.","volume":"91","author":"Dell","year":"2009","journal-title":"J Bone Joint Surg Am"},{"key":"R7-10-20210212","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bmj.312.7041.1254","article-title":"Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures.","volume":"312","author":"Marshall","year":"1996","journal-title":"BMJ"},{"key":"R8-10-20210212","first-page":"1968","article-title":"The inpatient consultation approach to osteoporosis treatment in patients with a fracture. Is automatic consultation needed?","volume":"88","author":"Streeten","year":"2006","journal-title":"J Bone Joint Surg Am"},{"key":"R9-10-20210212","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0002-9343(01)01124-X","article-title":"Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs.","volume":"112","author":"Cummings","year":"2002","journal-title":"Am J Med"},{"key":"R10-10-20210212","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s001980050104","article-title":"Correlation of femoral and lumbar DXA and calcaneal ultrasound, measured in situ with intact soft tissues, with the in vitro failure loads of the proximal femur.","volume":"8","author":"Lochmuller","year":"1998","journal-title":"Osteoporos Int"},{"key":"R11-10-20210212","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.288.15.1889","article-title":"Clinical use of bone densitometry: scientific review.","volume":"288","author":"Cummings","year":"2002","journal-title":"JAMA"},{"key":"R12-10-20210212","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.bone.2009.01.373","article-title":"FRAX and its applications to clinical practice.","volume":"44","author":"Kanis","year":"2009","journal-title":"Bone"},{"key":"R13-10-20210212","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00198-003-1506-0","article-title":"A comparison of different screening strategies to identify elderly women at high risk of hip fracture: results from the EPIDOS prospective study.","volume":"14","author":"Dargent-Molina","year":"2003","journal-title":"Osteoporos Int"},{"key":"R14-10-20210212","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/archinte.164.10.1108","article-title":"Bone mineral density thresholds for pharmacological intervention to prevent fractures.","volume":"164","author":"Siris","year":"2004","journal-title":"Arch Intern Med"},{"key":"R15-10-20210212","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clinthera.2004.12.020","article-title":"The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management.","volume":"27","author":"Felsenberg","year":"2005","journal-title":"Clin Ther"},{"key":"R16-10-20210212","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s00198-005-1992-3","article-title":"Comparison of mineral quality and quantity in iliac crest biopsies from high- and low-turnover osteoporosis: an FT-IR microspectroscopic investigation.","volume":"16","author":"Boskey","year":"2005","journal-title":"Osteoporos Int"},{"key":"R17-10-20210212","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1359\/jbmr.1997.12.11.1761","article-title":"Prevalence of low femoral bone density in older U.S. adults from NHANES III.","volume":"12","author":"Looker","year":"1997","journal-title":"J Bone Miner Res"},{"key":"R18-10-20210212","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.berh.2005.06.005","article-title":"The management of secondary osteoporosis.","volume":"19","author":"Kelman","year":"2005","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R19-10-20210212","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0025-6196(11)62214-3","article-title":"Secondary causes of osteoporosis.","volume":"77","author":"Fitzpatrick","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"R20-10-20210212","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/rheumatology\/34.10.936","article-title":"Aetiology and presenting symptoms in male osteoporosis.","volume":"34","author":"Peris","year":"1995","journal-title":"Br J Rheumatol"},{"key":"R21-10-20210212","first-page":"200","article-title":"Pathogenesis of vertebral crush fractures in women.","volume":"87","author":"Caplan","year":"1994","journal-title":"J R Soc Med"},{"key":"R22-10-20210212","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/qjmed\/hci096","article-title":"Vitamin D inadequacy among post-menopausal women: a systematic review.","volume":"98","author":"Gaugris","year":"2005","journal-title":"QJM"},{"key":"R23-10-20210212","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4065\/81.3.353","article-title":"High prevalence of vitamin D inadequacy and implications for health.","volume":"81","author":"Holick","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"R24-10-20210212","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1210\/jc.2004-2364","article-title":"Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy.","volume":"90","author":"Holick","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R25-10-20210212","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1056\/NEJMra070553","article-title":"Vitamin D deficiency.","volume":"357","author":"Holick","year":"2007","journal-title":"N Engl J Med"},{"key":"R26-10-20210212","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/art.27313","article-title":"Intracellular Na(+) and Ca(2+) modulation increases the tensile properties of developing engineered articular cartilage.","volume":"62","author":"Natoli","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R27-10-20210212","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1196\/annals.1346.039","article-title":"Bone strength: current concepts.","volume":"1068","author":"Turner","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"R29-10-20210212","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(08)61035-1","article-title":"Pathogenesis and management of Pagets disease of bone.","volume":"372","author":"Ralston","year":"2008","journal-title":"Lancet"},{"key":"R30-10-20210212","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0889-8529(18)30340-2","article-title":"Corticosteroid-induced osteoporosis.","volume":"19","author":"Hodgson","year":"1990","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R31-10-20210212","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s11926-008-0019-4","article-title":"Drug-induced osteoporosis: beyond glucocorticoids.","volume":"10","author":"Briot","year":"2008","journal-title":"Curr Rheumatol Rep"},{"key":"R32-10-20210212","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2796.2004.01434.x","article-title":"Effects of long-term treatment with loop diuretics on bone mineral density, calcitropic hormones and bone turnover.","volume":"257","author":"Rejnmark","year":"2005","journal-title":"J Intern Med"},{"key":"R33-10-20210212","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2796.2005.01585.x","article-title":"Fracture risk in patients treated with loop diuretics.","volume":"259","author":"Rejnmark","year":"2006","journal-title":"J Intern Med"},{"key":"R34-10-20210212","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00223-008-9170-1","article-title":"Acid-suppressive medications and risk of bone loss and fracture in older adults.","volume":"83","author":"Yu","year":"2008","journal-title":"Calcif Tissue Int"},{"key":"R35-10-20210212","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s00223-006-0021-7","article-title":"Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture.","volume":"79","author":"Vestergaard","year":"2006","journal-title":"Calcif Tissue Int"},{"key":"R36-10-20210212","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00198-004-1675-5","article-title":"Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review.","volume":"15","author":"Elliot-Gibson","year":"2004","journal-title":"Osteoporos Int"},{"key":"R38-10-20210212","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/jn\/135.2.317","article-title":"Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D.","volume":"135","author":"Hollis","year":"2005","journal-title":"J Nutr"},{"key":"R39-10-20210212","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/07315724.2003.10719287","article-title":"Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D.","volume":"22","author":"Heaney","year":"2003","journal-title":"J Am Coll Nutr"},{"key":"R40-10-20210212","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1302\/0301-620X.91B12.22481","article-title":"The level of vitamin D in the serum correlates with fatty degeneration of the muscles of the rotator cuff.","volume":"91","author":"Oh","year":"2009","journal-title":"J Bone Joint Surg Br"},{"key":"R41-10-20210212","first-page":"1","article-title":"Effectiveness and safety of vitamin D in relation to bone health.","volume":"158","author":"Cranney","year":"2007","journal-title":"Evid Rep Technol Assess (Full Rep)"},{"key":"R42-10-20210212","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1359\/jbmr.060607","article-title":"Association between serum 25(OH)D concentrations and bone stress fractures in Finnish young men.","volume":"21","author":"Ruohola","year":"2006","journal-title":"J Bone Miner Res"},{"key":"R43-10-20210212","doi-asserted-by":"crossref","first-page":"544","DOI":"10.4158\/EP.9.6.544","article-title":"American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003.","volume":"9","author":"Hodgson","year":"2003","journal-title":"Endocr Pract"},{"key":"R44-10-20210212","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"R45-10-20210212","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density.","volume":"346","author":"Reid","year":"2002","journal-title":"N Engl J Med"},{"key":"R46-10-20210212","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"R47-10-20210212","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s001980200068","article-title":"Biochemical indices of bone turnover and the assessment of fracture probability.","volume":"13","author":"Johnell","year":"2002","journal-title":"Osteoporos Int"},{"key":"R48-10-20210212","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy.","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"R49-10-20210212","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2106\/JBJS.I.00919","article-title":"The assessment of fracture risk.","volume":"92","author":"Unnanuntana","year":"2010","journal-title":"J Bone Joint Surg Am"},{"key":"R50-10-20210212","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1001\/jama.291.16.1999","article-title":"Effect of vitamin D on falls: a meta-analysis.","volume":"291","author":"Bischoff-Ferrari","year":"2004","journal-title":"JAMA"},{"key":"R51-10-20210212","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/jcb.10423","article-title":"New insights into the mechanisms of vitamin D action.","volume":"88","author":"Christakos","year":"2003","journal-title":"J Cell Biochem"},{"key":"R52-10-20210212","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/ajcn\/80.3.752","article-title":"Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged or =60 y60 y.","volume":"80","author":"Bischoff-Ferrari","year":"2004","journal-title":"Am J Clin Nutr"},{"key":"R53-10-20210212","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.2165\/00002512-200724120-00005","article-title":"Optimal vitamin D status for the prevention and treatment of osteoporosis.","volume":"24","author":"Holick","year":"2007","journal-title":"Drugs Aging"},{"key":"R54-10-20210212","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/ajcn\/77.1.204","article-title":"Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol.","volume":"77","author":"Heaney","year":"2003","journal-title":"Am J Clin Nutr"},{"key":"R55-10-20210212","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1093\/ajcn\/77.6.1478","article-title":"Fortification of orange juice with vitamin D: a novel approach for enhancing vitamin D nutritional health.","volume":"77","author":"Tangpricha","year":"2003","journal-title":"Am J Clin Nutr"},{"key":"R56-10-20210212","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/ajcn\/69.1.74","article-title":"Vitamin K intake and hip fractures in women: a prospective study.","volume":"69","author":"Feskanich","year":"1999","journal-title":"Am J Clin Nutr"},{"key":"R57-10-20210212","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11914-009-0020-5","article-title":"Osteoporosis prevention and nutrition.","volume":"7","author":"Tucker","year":"2009","journal-title":"Curr Osteoporos Rep"},{"key":"R58-10-20210212","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/107110079401500202","article-title":"2nd, et al. Cigarette smoking and nonunion after ankle arthrodesis.","volume":"15","author":"Cobb","year":"1994","journal-title":"Foot Ankle Int"},{"key":"R59-10-20210212","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3945\/ajcn.2008.26765","article-title":"Effects of beer, wine, and liquor intakes on bone mineral density in older men and women.","volume":"89","author":"Tucker","year":"2009","journal-title":"Am J Clin Nutr"},{"key":"R60-10-20210212","doi-asserted-by":"crossref","first-page":"450","DOI":"10.5435\/00124635-200708000-00002","article-title":"The effects of medications on bone.","volume":"15","author":"Goodman","year":"2007","journal-title":"J Am Acad Orthop Surg"},{"key":"R61-10-20210212","first-page":"CD005088","article-title":"Bisphosphonate therapy for osteogenesis imperfecta.","volume":"4","author":"Phillipi","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"R62-10-20210212","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"R63-10-20210212","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"R64-10-20210212","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00223-004-0286-7","article-title":"Seven years of treatment with risedronate in women with postmenopausal osteoporosis.","volume":"75","author":"Mellstrom","year":"2004","journal-title":"Calcif Tissue Int"},{"key":"R65-10-20210212","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/s00198-004-1770-7","article-title":"Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial.","volume":"16","author":"Chapurlat","year":"2005","journal-title":"Osteoporos Int"},{"key":"R66-10-20210212","first-page":"605","article-title":"Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.","volume":"14","author":"Tosteson","year":"2008","journal-title":"Am J Manag Care"},{"key":"R67-10-20210212","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1359\/jbmr.090209","article-title":"Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture.","volume":"24","author":"Eriksen","year":"2009","journal-title":"J Bone Miner Res"},{"key":"R68-10-20210212","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1359\/jbmr.070318","article-title":"Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair.","volume":"22","author":"Amanat","year":"2007","journal-title":"J Bone Miner Res"},{"key":"R69-10-20210212","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.bone.2008.05.019","article-title":"Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling.","volume":"43","author":"McDonald","year":"2008","journal-title":"Bone"},{"key":"R70-10-20210212","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdj105","article-title":"Management of the adverse effects associated with intravenous bisphosphonates.","volume":"17","author":"Tanvetyanon","year":"2006","journal-title":"Ann Oncol"},{"key":"R71-10-20210212","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00198-008-0805-x","article-title":"Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study.","volume":"20","author":"Lenart","year":"2009","journal-title":"Osteoporos Int"},{"key":"R72-10-20210212","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/BOT.0b013e318172841c","article-title":"Low-energy femoral shaft fractures associated with alendronate use.","volume":"22","author":"Neviaser","year":"2008","journal-title":"J Orthop Trauma"},{"key":"R74-10-20210212","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/jc.2009-1947","article-title":"Long-term use of bisphosphonates in osteoporosis.","volume":"95","author":"Watts","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"R75-10-20210212","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"R76-10-20210212","first-page":"731","article-title":"Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34).","volume":"87","author":"Alkhiary","year":"2005","journal-title":"J Bone Joint Surg Am"},{"key":"R77-10-20210212","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1359\/jbmr.1999.14.6.960","article-title":"Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures.","volume":"14","author":"Andreassen","year":"1999","journal-title":"J Bone Miner Res"},{"key":"R78-10-20210212","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3109\/17453671003761946","article-title":"Teriparatide improves early callus formation in distal radial fractures.","volume":"81","author":"Aspenberg","year":"2010","journal-title":"Acta Orthop"},{"key":"R79-10-20210212","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1359\/jbmr.080506","article-title":"Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment.","volume":"23","author":"Obermayer-Pietsch","year":"2008","journal-title":"J Bone Miner Res"},{"key":"R80-10-20210212","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/BOR.0b013e32832ca41c","article-title":"Denosumab update.","volume":"21","author":"Lewiecki","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"R81-10-20210212","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.","volume":"26","author":"Ellis","year":"2008","journal-title":"J Clin Oncol"},{"key":"R82-10-20210212","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer.","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"key":"R83-10-20210212","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMra067395","article-title":"Mechanisms of anabolic therapies for osteoporosis.","volume":"357","author":"Canalis","year":"2007","journal-title":"N Engl J Med"},{"key":"R84-10-20210212","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1517\/14728220902841961","article-title":"Wnt signaling as a therapeutic target for bone diseases.","volume":"13","author":"Hoeppner","year":"2009","journal-title":"Expert Opin Ther Targets"},{"key":"R85-10-20210212","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.","volume":"24","author":"Li","year":"2009","journal-title":"J Bone Miner Res"},{"key":"R86-10-20210212","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2006-09-047712","article-title":"Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo.","volume":"109","author":"Yaccoby","year":"2007","journal-title":"Blood"},{"key":"R87-10-20210212","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nm.2098","article-title":"Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis.","volume":"16","author":"Yadav","year":"2010","journal-title":"Nat Med"}],"container-title":["Journal of Orthopaedic Trauma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00005131-201109000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:31:53Z","timestamp":1786044713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005131-201109000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":83,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/bot.0b013e3181f9b389","relation":{},"ISSN":["0890-5339"],"issn-type":[{"value":"0890-5339","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}